Give Avanir Some Time

Avanir’s Nuedexta, recently approved for the treatment of Pseudobulbar Affect (PBA), falls short of market expectations. Despite rising sales, Nuedexta is under-prescribed for ALS, MS, and other neurological disease in which patients experience uncontrolled outbursts of laughing or crying. Avanir believes that the problem is simply a matter of educating medical professionals about the disorder and the options for treatment, given the robust efficacy of the drug.

Click here to read more.

Share this: